Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

DSM and Crucell announce new CEO and establishment of PER.C6 R&D Center in Boston area

DSM Coating Resins : 28 June, 2006  (New Product)
Dutch biotechnology company Crucell N.V. and its technology partner DSM Biologics BV, a business unit of Royal DSM N.V., announced today that Dr. Marco Cacciuttolo has accepted the position of Chief Executive Officer of their joint PER.C6 R&D Center, which will be located in Cambridge, MA. Dr. Cacciuttolo joins the venture with over ten years of experience in technical operations within the biotech and pharmaceutical industries.
Dr. Cacciuttolo has occupied positions of increasing responsibility at MedImmune, Inc, and most recently at Medarex, Inc. as the Vice President of Technical Operations. Dr. Cacciuttolo received his Ph.D. in Biochemical Engineering from the University of Maryland, Baltimore County and his B.S. in Biochemical Engineering from the Catholic University of Valparaiso, Valparaiso, Chile.

The Cambridge, Massachusetts location for the R&D center was specifically selected due to its outstanding scientific resources and world-class talent pool.

We are delighted to bring Marco Cacciuttolo on board as CEO. He has a strong track record in the biotech industry, and will provide strong leadership to the technology venture, says Dr. Leendert Staal, President and CEO of DSM Pharmaceutical Products. We are excited with the move to the Boston area, which marks an important next step in the development of our joint venture with Crucell.

The new R&D center will specialize in the further development of the PER.C6 human cell line to make it the premier system for the expression of recombinant pharmaceutical proteins. This center of excellence will provide a fully integrated technology platform, and true turn-key solutions for the production of pharmaceutical proteins, to the biotech industry and the scientific community. This PER.C6 technology platform will comprise cell line generation technology, tailored cell culture media, fermentation processes, equipment design, scale-up, technology transfer, and regulatory support. The R&D center will have dedicated space for PER.C6 users to experience the technology hands on.

Dr. Marco Cacciuttolo, Chief Executive Officer of the R&D Center, stated, ' I welcome the opportunity to strengthen the technological possibilities that PER.C6 offers to the entire biotechnology industry as a premier expression system for fully human proteins.

Ronald Brus, Managing Director and CEO of Crucell, states: We are excited about the choice of location. Not only are we building on and adding to the depth and strength of bio-sciences in the Boston area, but this is a major milestone in supporting the growing number of licensees for PER.C6.

The fit-out of the new center will take place over the coming months. Recruitment of some 50 scientific and support staff has started and commencement of operations is expected before the end of 2006.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo